Wlodarski Marcin Wojciech, Nearman Zachary, Jiang Ying, Lichtin Alan, Maciejewski Jaroslaw Pawel
Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center of the Cleveland Clinic, Cleveland, OH 44195, USA.
Exp Hematol. 2008 Mar;36(3):293-300. doi: 10.1016/j.exphem.2007.11.011.
T-cell-mediated autoimmunity may be involved in some cases of idiopathic neutropenia. We hypothesized that a precise T-cell receptor repertoire analysis may uncover cytotoxic T-cell (CTL) expansions that are less pronounced than those seen in T large granular lymphocyte leukemia (T-LGL), but are pathophysiologically analogous and thus can serve as markers of a T-cell-mediated process.
Using rational algorithms for T-cell receptor analysis and in vivo tracking of CTL responses previously established in our laboratory, we studied patients with unexplained chronic neutropenia (n = 20), T-LGL (n = 15), and healthy controls (n = 12). We further investigated the involvement of soluble inhibitory factors by coculture assays. To determine the level of immune activation, we studied interferon-gamma expression in CD8(+)cells using Taqman polymerase chain reaction.
Fifteen expanded (immunodominant) CTL clones were detected in 12 of 20 patients. In comparison to LGL leukemia, these clones were less immunodominant, but clearly discernible from subclinical lymphoproliferations in controls. As a surrogate of cytotoxic activity, we found markedly increased production of interferon-gamma in most of the neutropenia patients, irrespective of the presence of immunodominant CTL clones.
These results suggest that, while immunodominant CTL clones are detectable in a proportion of patients only, CTL-mediated pathophysiology may be a general mechanism operating in idiopathic neutropenia. Oligogoclonal CTL expansions in chronic neutropenia may indicate an ongoing autoimmune process, while highly polarized monoclonalities in a subset of neutropenic LGL patients may represent the "extreme" end of the clonal continuum.
T细胞介导的自身免疫可能在某些特发性中性粒细胞减少症病例中起作用。我们推测,精确的T细胞受体谱分析可能会发现细胞毒性T细胞(CTL)扩增,其程度不如T大颗粒淋巴细胞白血病(T-LGL)中明显,但在病理生理学上类似,因此可作为T细胞介导过程的标志物。
使用我们实验室先前建立的用于T细胞受体分析的合理算法和CTL反应的体内追踪,我们研究了不明原因慢性中性粒细胞减少症患者(n = 20)、T-LGL患者(n = 15)和健康对照者(n = 12)。我们通过共培养试验进一步研究了可溶性抑制因子的参与情况。为了确定免疫激活水平,我们使用Taqman聚合酶链反应研究了CD8(+)细胞中干扰素-γ的表达。
在20例患者中的12例中检测到15个扩增的(免疫显性)CTL克隆。与LGL白血病相比,这些克隆的免疫显性较低,但与对照组的亚临床淋巴细胞增殖明显不同。作为细胞毒性活性的替代指标,我们发现大多数中性粒细胞减少症患者中干扰素-γ的产生明显增加,无论是否存在免疫显性CTL克隆。
这些结果表明,虽然仅在一部分患者中可检测到免疫显性CTL克隆,但CTL介导的病理生理学可能是特发性中性粒细胞减少症中起作用的一般机制。慢性中性粒细胞减少症中的寡克隆CTL扩增可能表明正在进行的自身免疫过程,而一部分中性粒细胞减少LGL患者中的高度极化单克隆性可能代表克隆连续体的“极端”末端。